Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review

摘要: Medical advances in pediatric oncology have led to increases survival but the long-term adverse effects of treatment childhood cancer survivors not yet been examined depth. In this systematic review, we aimed study prevalence and risk factors late-onset cardiomyopathy (LOCM) among lymphoma treated with anthracyclines. Following Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines searched Pubmed/Medline, abstracted data rated studies on quality regarding (>1 year following treatment) cardiotoxicity anthracyclines lymphoma. Across 22 identified studies, anthracycline-induced LOCM ranges from 0 40%. Anthracycline dose, administration dose mediastinal radiation, patient's age era diagnosis evaluation, follow-up duration as well disease relapse reported LOCM, whereas dexrazoxane seems act protectively. There was significant between-study heterogeneity regards subtypes, duration, definition outcomes, anthracycline-based protocols. The rates are high dependent design. Future should explore whether modifying suggested supportive care could decrease its survivors. Until then, lifelong these patients aiming determinate earliest signs cardiac dysfunction is most important measure towards primordial prevention LOCM.